Parallel Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-92,323
| Closed | -$281K | – | 3718 |
|
|
2024
Q4 | $281K | Hold |
92,323
| – | – | 0.01% | 791 |
|
|
2024
Q3 | $479K | Hold |
92,323
| – | – | 0.01% | 581 |
|
|
2024
Q2 | $237K | Buy |
+92,323
| New | +$315K | 0.01% | 800 |
|
|
2024
Q1 | – | Sell |
-327
| Closed | -$2.87K | – | 3438 |
|
|
2023
Q4 | $2.87K | Buy |
+327
| New | +$2.68K | ﹤0.01% | 2688 |
|
|
2023
Q2 | – | Sell |
-11
| Closed | -$354 | – | 3550 |
|
|
2023
Q1 | $354 | Buy |
+11
| New | +$343 | ﹤0.01% | 3209 |
|
|
2022
Q1 | – | Sell |
-308
| Closed | -$5K | – | 3327 |
|
|
2021
Q4 | $5K | Sell |
308
-2,045
| -87% | -$34.1K | ﹤0.01% | 2434 |
|
|
2021
Q3 | $66K | Buy |
2,353
+163
| +7% | +$4.65K | ﹤0.01% | 1163 |
|
|
2021
Q2 | $65K | Buy |
+2,190
| New | +$63.2K | ﹤0.01% | 1124 |
|
|
2020
Q4 | – | Sell |
-383
| Closed | -$10K | – | 2756 |
|
|
2020
Q3 | $10K | Hold |
383
| – | – | ﹤0.01% | 1757 |
|
|
2020
Q2 | $9K | Hold |
383
| – | – | ﹤0.01% | 1777 |
|
|
2020
Q1 | $5K | Hold |
383
| – | – | ﹤0.01% | 1928 |
|
|
2019
Q4 | $6K | Hold |
383
| – | – | ﹤0.01% | 1931 |
|
|
2019
Q3 | $5K | Buy |
383
+230
| +150% | +$2.81K | ﹤0.01% | 1948 |
|
|
2019
Q2 | $2K | Buy |
+153
| New | +$1.93K | ﹤0.01% | 2139 |
|
Other funds holding RVNC
Parallel Advisors's RVNC Position: Q1 2025 in Review
Parallel Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 92,323 shares — an estimated $281K sold.
Parallel Advisors first reported a position in RVNC in Q2 2019 and held it in 14 quarters. The position peaked at $479K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Parallel Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Parallel Advisors sold 92,323 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $281K.
- Parallel Advisors first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 14 quarters.
- Parallel Advisors's Revance Therapeutics, Inc. position peaked at $479K in Q3 2024.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.